— Zantac · ranitidine NDMA cancer claims
It lived in the kitchen drawer for twenty years. After dinner, after a late curry, whenever the burning came back. Nobody ever suggested there was anything to it. Then came a diagnosis, and then somebody mentioned a recall you half-remembered from 2020.
🔒 Encrypted & handled per our Privacy Policy
Total cases filed in the
federal MDL 2924
Still pending there
as of July 2026
GSK settlement covering roughly
80,000 already-filed claims
Upfront cost to have
your case reviewed
These claims are about long-term ranitidine use followed by cancer. Before the criteria, one thing has to be said plainly: this litigation has gone badly for claimants, and for most people the honest answer is that there is no longer a case to bring.
Meeting these guidelines does not mean you have a valid claim, and in this litigation it may not even mean a firm will review it. The federal court and the Delaware courts both excluded the plaintiffs’ scientific experts on whether ranitidine causes cancer. Those rulings apply no matter how strong an individual person’s facts are, and most law firms have closed Zantac intake as a result. Any firm that does review your case decides on its own whether to take it. Direct2Attorney cannot judge the legal merits of your case, give legal advice, or file anything for you.
Call and ask one question: given my state and my diagnosis date, is there anything left to file? A participating firm can usually answer that in a few minutes, and the answer may well be no.
— Educational
Ranitidine has not been sold in the United States since April 2020, so there is nothing for you to stop taking. If you are using something for heartburn today, it is a different medicine. Famotidine, sold as Pepcid and as the current Zantac 360 product, is a different molecule and was not part of the recall.
If you took ranitidine for years and you are worried, the useful step is a conversation with your doctor about whether any screening makes sense for you, based on your age, your family history and your symptoms. That is a medical conversation, and it is separate from any legal question. Nothing on this page is medical advice.
Zantac was ranitidine, an H2 blocker that reduces stomach acid. Approved in 1983, it became one of the best-selling drugs in the world and was available without a prescription for decades. Tens of millions of people took it, many of them for years.
In 2019 an independent pharmacy laboratory reported that ranitidine could break down into NDMA — N-nitrosodimethylamine, a compound classified as a probable human carcinogen — and petitioned the FDA to act. The concern was that the molecule was unstable, and that heat and time during storage could increase how much NDMA formed.
On April 1, 2020 the FDA requested that all ranitidine products be withdrawn from the U.S. market. The agency cited its own testing showing NDMA levels increasing in samples stored at higher temperatures and over time. Every ranitidine product came off American shelves.
The lawsuits followed almost immediately. What happened to them since is the part most pages leave out.
That the manufacturers knew or should have known ranitidine was chemically unstable, that it degraded into NDMA in storage and possibly in the body, and that they failed to test adequately or warn anyone, while continuing to sell it for decades.
Claimants pointed to the FDA’s own findings and to the withdrawal itself as evidence that the risk was real and that the product should never have stayed on the market as long as it did.
That the expert evidence offered to prove ranitidine causes cancer was not reliable enough to reach a jury. The federal judge found the plaintiffs’ experts made analytical leaps, leaned on weak epidemiology, and set aside larger studies that did not help them.
Delaware’s Supreme Court later reached a similar place, holding there is no presumption favoring admission of expert opinion. This is a ruling about proof, not a finding that the drug was safe — but in practice the effect on claims is the same.
Federal cases were consolidated as MDL 2924 before Judge Robin L. Rosenberg in the Southern District of Florida. On December 6, 2022 she issued a 341-page opinion excluding all ten of the plaintiffs’ general causation experts under the Daubert standard, and granted summary judgment for the manufacturers. Roughly 50,000 claims fell with it. Of 15,018 cases filed in that MDL over its life, about 847 remained pending as of July 2026.
Plaintiffs appealed. The Eleventh Circuit heard oral argument on October 10, 2025 and had not issued a decision as of the last check before this page was published. That ruling is the single biggest open variable in this litigation. If the exclusion is reversed, the federal track reopens. If it is affirmed, it closes for good.
Delaware became the center of gravity after the federal ruling, holding tens of thousands of cases. In May 2024 the Superior Court allowed the plaintiffs’ experts to testify, which briefly revived the litigation nationally. The Delaware Supreme Court reversed that decision in July 2025, holding that the trial court had applied the wrong standard.
On remand the experts were excluded, and in April 2026 the Superior Court granted summary judgment, dismissing more than 80,000 claims against Boehringer Ingelheim covering everything filed before December 2025. Appeals from those rulings are possible, but as things stand the Delaware route is shut.
In October 2024 GSK agreed to pay up to approximately $2.2 billion to resolve around 80,000 cases, roughly 93% of the state court claims against it. Sanofi and Pfizer separately resolved thousands more in 2024 and 2025. These were private deals for specific inventories of already-filed cases, negotiated with particular firms.
There is no open fund and no claims process to apply to. Boehringer Ingelheim, the one major defendant that did not settle, has taken cases to trial and won a run of defense verdicts in Illinois and California. A verdict for a Zantac claimant has been the exception, not the rule.
Put the two problems together. The causation rulings do not depend on your individual facts — however clear your use history and however serious your diagnosis, the same expert evidence has been rejected twice by two different court systems. And ranitidine left the market in April 2020, so in many states the filing deadline has already run for a cancer diagnosed years ago.
That does not make every claim impossible. Some state courts have not ruled the same way, wrongful death deadlines can run from a later date, and the Eleventh Circuit could change the picture. But most law firms have stopped taking Zantac cases, and you should treat any service promising you a Zantac payout with real suspicion. What is worth having is a straight answer about whether anything remains open for you. A firm can give you that, and it costs nothing.
No court has found that ranitidine causes cancer. It is equally true that no court has found it does not. What the courts decided is narrower and more technical: that the specific scientific evidence the plaintiffs offered was not reliable enough to be presented to a jury. The FDA’s withdrawal request in 2020 was a precautionary action about NDMA levels in the product, not a finding that anyone’s cancer was caused by it. If you have health concerns about a medication you took, that is a question for your doctor, not for a legal page. This page is general information, not medical advice.
— Compensation
Where a claim succeeds, compensation is meant to cover what a cancer diagnosis has cost. Read this section knowing that in this particular litigation, very few claims have reached that point.
— The process
You do not need pharmacy records or a case number to begin. Tell us what you remember, and expect a candid answer.
Roughly how many years you took Zantac or ranitidine, and when you were diagnosed. Two minutes, no cost, no obligation. Approximate dates are fine.
Given where this litigation is, the most useful thing a firm can do is tell you quickly whether anything is still open in your state. If the answer is that there is nothing to pursue, you should hear it on that first call rather than after weeks of waiting.
You sign an authorization. The firm requests pharmacy and prescription records to establish use, plus pathology, imaging and treatment records for the diagnosis.
Your case is filed in whichever court remains viable, and your firm keeps you updated, including on the pending federal appeal. You are never required to accept an offer you do not want.
💰
The review is free. Participating firms work on contingency, so a fee is owed only out of a recovery. No recovery, no attorney fee.
⚖️
Most firms have closed Zantac intake. We would rather tell you that than take your details and leave you waiting for a call that is not coming.
If a Zantac claim is not viable but something else in your history is, a participating firm can look at that instead.
Medical history is personal. Your information is encrypted and handled according to our Privacy Policy.
What Direct2Attorney is
A legal marketing and referral service. We check whether your situation matches what participating law firms are looking for, and connect you with one of them if it does.
What Direct2Attorney is not
We are not a law firm. We cannot give you legal advice, represent you, or file anything on your behalf. Only a law firm you sign with can do that.
If you took Zantac for years and were later diagnosed with cancer, you are entitled to know exactly where this litigation stands rather than a sales pitch about it. For many people the answer will be that the door has closed. For some it has not. Finding out takes about two minutes and costs nothing.
Only barely, and it depends entirely on where you are. The federal MDL was effectively ended in December 2022 when the judge excluded all of the plaintiffs’ general causation experts, and that ruling is on appeal to the Eleventh Circuit, which heard argument in October 2025 and had not issued a decision as of mid-2026. Delaware, which held tens of thousands of cases, dismissed them in April 2026 after its Supreme Court tightened the expert standard. Most law firms have closed Zantac intake. Some claims continue in other state courts. Anyone who tells you this litigation is wide open is not describing it accurately.
Where firms are still reviewing claims at all, they generally look for long-term use of brand-name Zantac or generic ranitidine, usually a year or more, followed by a diagnosis of one of the cancers commonly alleged in this litigation, such as bladder, stomach, esophageal, liver, pancreatic or colorectal cancer, with a plausible latency period between use and diagnosis. Proof of use matters, so pharmacy records, prescription histories or receipts help. Meeting these criteria does not mean a firm will take the case, because the causation rulings apply regardless of individual facts.
They were dismissed. In December 2022 Judge Robin L. Rosenberg, who oversaw MDL 2924 in the Southern District of Florida, issued a lengthy opinion excluding every one of the plaintiffs’ general causation experts under the Daubert standard, finding their methods unreliable. Without expert testimony that ranitidine can cause cancer, the claims could not proceed, and summary judgment was entered for the manufacturers. Roughly 50,000 claims were affected. Plaintiffs appealed, and the Eleventh Circuit heard oral argument in October 2025.
There were settlements, but they were private deals covering claims that were already filed, and they are closed. In October 2024 GSK agreed to pay up to approximately $2.2 billion to resolve about 80,000 cases, most of them in Delaware. Sanofi and Pfizer separately resolved thousands more. These were negotiated with specific firms for specific case inventories. There is no open claims process, no fund accepting new applications, and no mechanism for someone filing today to join them. Boehringer Ingelheim, the remaining major defendant, has not settled and has won a series of defense verdicts at trial.
For most people, realistically yes, and you deserve to hear that plainly. Two things stand in the way. First, the causation rulings in the federal MDL and in Delaware make it very difficult to prove the scientific link in court, and those rulings do not depend on your individual facts. Second, ranitidine was pulled from the U.S. market in April 2020, so the filing deadline has expired in many states for cancers diagnosed years ago. A firm can tell you in one call whether your state and your diagnosis date leave any path open. That call costs nothing, and an honest answer may be that there is nothing to pursue.
The cancers most commonly alleged were bladder, stomach, esophageal, liver, pancreatic and colorectal cancer, with some claims involving prostate and breast cancer. Courts narrowed the list over time. It is important to understand that no court has found that ranitidine causes any of these cancers. The federal court and the Delaware courts reached the opposite conclusion about the reliability of the scientific evidence offered to prove it.
No. The concern was specific to ranitidine, the active ingredient in Zantac, which can degrade into NDMA. Famotidine, sold as Pepcid and as Zantac 360, is a different molecule and was not part of the recall or the litigation. Zantac branded products sold in the United States today contain famotidine, not ranitidine. If you have questions about your own medication, ask your doctor or pharmacist. Nothing here is medical advice.
That depends on which court dismissed it and whether an appeal is still live. Claims dismissed in the federal MDL are covered by the pending Eleventh Circuit appeal, and the outcome of that appeal affects them as a group. The Delaware dismissals in April 2026 were entered with prejudice and appeals from them are possible. If you already had a lawyer, that firm is the right first call, since it knows the posture of your specific case.
Nothing to ask. The case review is free with no obligation. If a participating law firm takes your case, it will normally work on contingency. That means the fee comes out of a recovery, and no fee is owed if there is no recovery. Given the current state of this litigation, many firms will decline to take Zantac cases at all, and you should expect that as a realistic outcome.
No. Direct2Attorney is a legal marketing and referral service, not a law firm. An attorney-client relationship may form only after a participating law firm reviews your information and signs a separate representation agreement with you.
Ask it on the call. The review is free, and there is no obligation to move forward.
— News & updates
The 2025 Zantac settlement is unfolding as GSK addresses thousands of cancer-related lawsuits. With major payouts made and claims still
Fighting for Accountability After NDMA Cancer Risks A Hidden Danger Zantac, a heartburn drug used by millions, has sparked over
